Analytical method and kit

A method for differentially detecting pancreatic cancer in a subject who has a cancer comprising:

• quantifying an amount of hsa-miR-122-5p in a sample from the subject and comparing the amount of hsa-miR-122-5p in the sample to an amount of hsa-miR-122-5p in non-pancreatic cancer individuals having breast cancer, colon cancer, lung cancer, ovarian cancer, prostate cancer, bile duct cancer, esophagus cancer, liver cancer, brain tumor, bladder cancer, sarcoma, endometrial cancer or uterus sarcoma;
• and
• detecting pancreatic cancer where the quantified amount of hsa-miR-122-5p in the sample exceeds the amount of hsa-miR-122-5p in the non-pancreatic cancer individuals;
• wherein quantifying the amount of hsa-miR-122-5p in the sample from the subject is carried out using a primer set;
• and
• wherein the primer set contains:
• an FIP primer comprising SEQ ID NO. 6, a BIP primer comprising SEQ ID NO. 7, an LB primer comprising SEQ ID NO. 8, the reverse transcription primer comprising SEQ ID NO. 2, and the elongation primer comprising SEQ ID NO. 3,
• an FIP primer comprising SEQ ID NO. 6, a BIP primer comprising SEQ ID NO. 7, an LB primer comprising SEQ ID NO. 9, the reverse transcription primer comprises SEQ ID NO. 2, and the elongation primer comprising SEQ ID NO. 3, or
• an FIP primer comprising SEQ ID NO. 10, a BIP primer comprising SEQ ID NO. 11, an LB primer comprising SEQ ID NO. 8, the reverse transcription primer comprising SEQ ID NO. 4, and the elongation primer comprising SEQ ID NO. 5.